Pascal R. Hammel
Impact in
- Oncology top 0.05%
- Pancreatic and Hepatic Oncology Research
- PARP inhibition in cancer therapy
- Colorectal Cancer Treatments and Studies
- Epidemiology top 0.5%
- Neuroendocrine Tumor Research Advances
Papers in
- Oncology 231
- Pancreatic and Hepatic Oncology Research 194
- PARP inhibition in cancer therapy 13
- Colorectal Cancer Treatments and Studies 10
- Epidemiology 70
- Neuroendocrine Tumor Research Advances 69
- Co-authors
- Philippe B Ruszniewski (151 shared papers)Philippe Lévy (110 shared papers)Alain Sauvanet (71 shared papers)Frédérique Maire (51 shared papers)Anne Couvelard (82 shared papers)Dermot O’Toole (41 shared papers)Olivia Hentic (62 shared papers)Eric Van Cutsem (21 shared papers)
- Journals
- Annals of Oncology (30 papers)Pancreatology (18 papers)Journal of Clinical Oncology (16 papers)Pancreas (14 papers)The American Journal of Gastroenterology (13 papers)
- Partner nations
- FranceBelgiumUnited States
In The Last Decade
Pascal R. Hammel
358 papers receiving 26.8k citations
Pascal R. Hammel's Hit Papers
Peers
Comparison fields: 5 of 126
- Oncology 16k
- Epidemiology 3.8k
- Surgery 3.5k
- Hepatology 651
- Cancer Research 968
Countries citing papers authored by Pascal R. Hammel
This map shows the geographic impact of Pascal R. Hammel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Pascal R. Hammel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Pascal R. Hammel more than expected).
Fields of papers citing papers by Pascal R. Hammel
This network shows the impact of papers produced by Pascal R. Hammel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Pascal R. Hammel. The network helps show where Pascal R. Hammel may publish in the future.
Co-authors
The 25 scholars most cited alongside Pascal R. Hammel, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 380 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer Hit paper breakdown → | 2018 | 2184 |
| 2 | Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors Hit paper breakdown → | 2011 | 2044 |
| 3 | Maintenance Olaparib for Germline BRCA -Mutated Metastatic Pancreatic Cancer Hit paper breakdown → | 2019 | 1784 |
| 4 | Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial Hit paper breakdown → | 2017 | 1525 |
| 5 | Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib Hit paper breakdown → | 2016 | 827 |
| 6 | Gemcitabine in Combination With Oxaliplatin Compared With Gemcitabine Alone in Locally Advanced or Metastatic Pancreatic Cancer: Results of a GERCOR and GISCAD Phase III Trial Hit paper breakdown → | 2005 | 817 |
| 7 | 2008 | 569 | |
| 8 | nab-Paclitaxel Plus Gemcitabine for Metastatic Pancreatic Cancer: Long-Term Survival From a Phase III Trial Hit paper breakdown → | 2015 | 565 |
| 9 | 2007 | 422 | |
| 10 | Gemcitabine and Oxaliplatin Chemotherapy or Surveillance in Resected Biliary Tract Cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): A Randomized Phase III Study Hit paper breakdown → | 2019 | 410 |
| 11 | Randomized Phase III Trial of Pegvorhyaluronidase Alfa With Nab-Paclitaxel Plus Gemcitabine for Patients With Hyaluronan-High Metastatic Pancreatic Adenocarcinoma Hit paper breakdown → | 2020 | 385 |
| 12 | 2002 | 353 | |
| 13 | 2000 | 349 | |
| 14 | 2001 | 343 | |
| 15 | Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial Hit paper breakdown → | 2014 | 337 |
| 16 | 2000 | 311 | |
| 17 | 2000 | 306 | |
| 18 | 2017 | 284 | |
| 19 | 2001 | 275 | |
| 20 | 2000 | 253 |
About Pascal R. Hammel
Pascal R. Hammel is a scholar working on Oncology, Epidemiology, Surgery, Pulmonary and Respiratory Medicine and Rheumatology, having authored 380 papers that have together received 27.6k indexed citations. Recurring topics across this work include Pancreatic and Hepatic Oncology Research (194 papers), Neuroendocrine Tumor Research Advances (69 papers), Pancreatitis Pathology and Treatment (38 papers), PARP inhibition in cancer therapy (13 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (12 papers), Colorectal Cancer Treatments and Studies (10 papers), IgG4-Related and Inflammatory Diseases (10 papers) and Genetic factors in colorectal cancer (8 papers). The work is most often cited by research in Oncology (16k citations), Epidemiology (3.8k citations), Surgery (3.5k citations), Hepatology (651 citations) and Cancer Research (968 citations). Pascal R. Hammel has collaborated with scholars based in France, Belgium and United States. Frequent co-authors include Philippe B Ruszniewski, Philippe Lévy, Alain Sauvanet, Frédérique Maire, Anne Couvelard, Dermot O’Toole, Olivia Hentic, Eric Van Cutsem, Vinciane Rebours and Pierre Bernades. Their work appears in journals such as Annals of Oncology, Pancreatology, Journal of Clinical Oncology, Pancreas and The American Journal of Gastroenterology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.